Just a few years ago, there were no drugs available for patients with the rare genetic disease spinal muscular atrophy. Now two cutting-edge therapies look headed for a commercial battle, with each data and revenue update a key moment in the race.
Biogen (NASDAQ: BIIB) was the first to bring an SMA drug to market, the RNA drug nusinersen (Spinraza), a chronic treatment that has shown an ability to help people with multiple forms of the progressive disease. But sales of the landmark drug are slowing, and there is pressure building from rival AveXis (NASDAQ: AVXS), the Chicago-based… Read more »
UNDERWRITERS AND PARTNERS